6998.HK Stock Analysis
69
Uncovered
Genor Biopharma Holdings Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Genor Biopharma Holdings Ltd. engages in the development and commercialization of oncology and autoimmune drugs. The company is headquartered in Shanghai, Shanghai and currently employs 452 full-time employees. The company went IPO on 2020-10-07. The firm focuses on the development and commercialization of oncology and autoimmune drugs. The firm's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The firm mainly conducts its businesses in the China market.